Ind-Swift Laboratories hit an upper circuit of 5% at Rs 21.65 after the company said its manufacturing facility at Derabassi in Punjab received establishment inspection report (EIR) from the US drug regulator.
The United States Food and Drug Administration (USFDA)'s inspection was conducted from 9 to 13 March 2020. The EIR has been issued without any FORM 483 observations.This is the sixth successful USFDA inspection completed by the company. Ind- Swift Supplies 15 APIs (Active Pharmaceutical Ingredients) to its customers based in the US. The APIs manufactured from the Derabassi facility are supplied to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe, the company said in a statement.
Ind-Swift Laboratories manufactures bulk drugs and intermediates. The company's product portfolio includes anti-infective, anti-allergy, analgesic and cardiovascular medicines.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)